Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
暂无分享,去创建一个
C. Stief | B. Gaillac | C. Stief | M. Emberton | C. Gratzke | A. Roosen | E. Barret | B. Gaillac | F. Benzaghou | E. Barret | M. Emberton | A. Noweski | A. Roosen | S. Lebdai | F. Benzaghou | M. Apfelbeck | C. Gratzke | A.R. Azzouzi | S. Lebdai | M. Apfelbeck | A. Azzouzi | A. Noweski
[1] Baris Turkbey,et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.
[2] Christopher D. Brown,et al. Low-grade prostate cancer diverges early from high grade and metastatic disease , 2014, Cancer science.
[3] Hugh J. Lavery,et al. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? , 2012, The Journal of urology.
[4] M Emberton,et al. Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. , 2012, The British journal of radiology.
[5] C. Moore,et al. Photodynamic therapy for prostate cancer—an emerging approach for organ‐confined disease , 2011, Lasers in surgery and medicine.
[6] Yipeng Hu,et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy , 2017, British Journal of Cancer.
[7] Yipeng Hu,et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. , 2011, The Journal of urology.
[8] D. Bostwick,et al. Understanding the pathological features of focality, grade and tumour volume of early‐stage prostate cancer as a foundation for parenchyma‐sparing prostate cancer therapies: active surveillance and focal targeted therapy , 2011, BJU international.
[9] C. Porter,et al. Longitudinal regret after treatment for low‐ and intermediate‐risk prostate cancer , 2017, Cancer.
[10] Nacim Betrouni,et al. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11 , 2011, Physics in medicine and biology.
[11] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[12] Hashim U. Ahmed,et al. Photodynamic therapy for focal ablation of the prostate , 2010, World Journal of Urology.
[13] P. Validire,et al. Morbidity of focal therapy in the treatment of localized prostate cancer. , 2013, European urology.
[14] Timothy J Wilt,et al. Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.
[15] Clare Allen,et al. TOOKAD® Soluble vascular‐targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer , 2013, BJU international.
[16] Steven J. M. Jones,et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. , 2013, The Journal of urology.
[17] Yipeng Hu,et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy , 2012, BJU international.
[18] C. Catalano,et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.
[19] Zeike A. Taylor,et al. MR to ultrasound registration for image-guided prostate interventions , 2012, Medical Image Anal..
[20] L. Holmberg,et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. , 2011, The Lancet. Oncology.
[21] P. Bigot,et al. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer , 2015, World Journal of Urology.
[22] Osamu Ukimura,et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. , 2012, European urology.
[23] Antonio Alcaraz,et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Oncology.
[24] C. Stief,et al. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure , 2015, World Journal of Urology.
[25] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[26] J. Trachtenberg,et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11‐vascular‐targeted photodynamic (VTP) therapy , 2015, BJU international.